Basilea berichtet über Veröffentlichung klinischer Daten zu den Krebsmedikamenten-Kandidaten BAL101553 für Glioblastome und Derazantinib für intrahepatische Cholangiokarzinome auf der ASCO-Tagung

NEXT STORY
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
PREV STORY
Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Photocure Announces U.S. FDA Approval of New Indications for Blue Light Cystoscopy with Cysview®

Oslo, Norway, February 16, 2018 Photocure ASA (OSE: PHO), announced today that the U.S. ...

author_avatar
NASDAQ Market News

Caladrius Biosciences Provides Year-End 2020 Strategic Portfolio Update

author_avatar
NASDAQ Market News

Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon

author_avatar
NASDAQ Market News